Visit go.covermymeds.com/OptumRx to begin using this free service

Xifaxan® Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Memb	Provider Information (required)					
Member Name:			Provider Name:			
Insurance ID#:			NPI#: Specialty:			
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	ZIP:	Office Street Address:			
Phone:	1	1	City: State: ZI		ZIP:	
		Medication Inf	formation (required	d)		
Medication Name:			Strength: Dosage Form:			
			Directions for Use:	Directions for Use:		
		Clinical Info	rmation			
1 Does the nation	t have a diagnosis of		rmation (required)			☐ Yes ☐ No
•	ring: Cipro (ciprofloxac	in) Levagi	ıin	☐ Yes ☐ No		
2. Has the patient had a trial and failure of ONE of the following: Cipro (ciprofloxacin), Levaquin (levofloxacin), Ofloxacin or Zithromax (azithromycin)?						
3. Does the patient have resistance, contraindication or intolerance to ALL of the following antibiotics: Cipro (ciprofloxacin), Levaquin (levofloxacin), Ofloxacin and Zithromax (azithromycin)?						☐ Yes ☐ No
4. Does the patient have a diagnosis of small bowel bacterial overgrowth/small intestinal bacterial overgrowth?						☐ Yes ☐ No
5. Has the patient l	had a trial and failure	of TWO of the follow	ving antibiotics?			☐ Yes ☐ No
_	n (amoxicillin/clavular	•	Keflex (cephalexin)			
	rimethoprim-sulfamet rofloxacin)	hoxazole) •	Neomycin Vibramycin (doxycy	cline) or M	inocin	
	etronidazole)		(minocycline) or teti	,		
6. Does the patient have resistance, contraindication or intolerance to ALL of the following antibiotics?						☐ Yes ☐ No
_	n (amoxicillin/clavulaı rimethoprim-sulfamet	•	Keflex (cephalexin) Neomycin			
	rofloxacin)	•	Vibramycin (doxycy	cline) or M	inocin	
- ,	etronidazole)		(minocycline) or teti			
	ion requests, is there of symptoms or relap		ositive clinical response ontinuation)?	e to Xifaxa	n therapy	☐ Yes ☐ No
8. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea?						☐ Yes ☐ No
9. Has the patient had a trial and failure, contraindication or intolerance to ONE of the following: Antidiarrheal agent (e.g., loperamide), antispasmodic agent (e.g., dicyclomine, hyoscyamine) or tricyclic antidepressant (amitriptyline)?						□ Yes □ No
10. For reauthorization requests, has the patient experienced irritable bowel syndrome with diarrhea symptom recurrence?						
11. Is Xifaxan being used for prophylaxis of hepatic encephalopathy recurrence?						
12. Is Xifaxan being used as add-on therapy to lactulose?						☐ Yes ☐ No

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Xifaxan_2019Dec

Xifaxan® Prior Authorization Request Form (Page 2 of 2)

13. Was the patient able to achieve an optimal clinical response with lactulose monotherapy?				
14. Does the patient have a history of contraindication or intolerance to lactulose?				
15. Is Xifaxan being used for the treatment of hepatic encephalopathy?	☐ Yes ☐ No			
16. Is Xifaxan being used as add-on therapy to lactulose?	☐ Yes ☐ No			
17. Was the patient able to achieve an optimal clinical response with lactulose	☐ Yes ☐ No			
18. Does the patient have a history of contraindication or intolerance to lactulo	☐ Yes ☐ No			
Prescriber's Signature:	Date:			
nformation on this form is accurate as of this date. Prescriber's Signature:	Date:			
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any this review?	other information the physici	ian feels is important to		
Places note: This request may be denied unless all required information is received				

For more information about the prior authorization process, please contact us at 855-811-2218. Monday - Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern